Theranos reached a settlement with the Centers for Medicare and Medicaid Services, which could make it eligible to operate a clinical lab within two years.
The U.S. government slightly improved its final payment rate for health insurers who offer Medicare Advantage plans for older people and the disabled, settling on an increase of 0.45 percent on average for 2018.
Spending on Rx drugs for health plans created under the ACA increased in 2016 at a rate more than three times that of other commercial plans and most government-run plans managed by Express Scripts Holding.
QuintilesIMS’ annual survey of pharmaceutical and device manufacturers was initiated in 2009 – when only a handful of U.S. states required disclosure of certain healthcare practitioner payments. Since then, of course, state, federal and global requirements have continually evolved and expanded. Our latest survey findings, which reflect responses from 112 manufacturers, underscore that while the bar keeps getting higher, manufacturers’ confidence and sophistication are also on the rise.
The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.
Mylan NV will pay $465 million to settle questions of whether it underpaid U.S. government healthcare programs by misclassifying its EpiPen emergency allergy treatment.
Nearly three-quarters of U.S. dermatologists received payments worth a collective $34 million from drug companies in 2014, according to a new analysis of a public database.
Healthcare spending in the United States will likely grow by an average 5.8 percent per year over the next decade according to updated projections from the federal government.
Elizabeth Holmes, the embattled CEO of blood testing company Theranos, will not be allowed to own or operate a blood testing laboratory for two years.
U.S. federal health regulators have proposed banning Theranos Inc founder Elizabeth Holmes from the blood-testing business for at least two years after determining that the company failed to fix deficiencies at its California laboratory, the Wall Street Journal reported on Wednesday. The Centers for Medicare and Medicaid (CMS) said in letter dated March 18 that […]